ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.768,96
0,33%
S&P 500
5.311,84
0,16%
Dow Jones
39.854,73
-0,37%
Euro vs US Dollar
1,08625
-0,11%
Bitcoin
68.499,50
3,54%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Urovant Sciences Ltd (UROV)

  7. Urovant Sciences Ltd (UROV) News

UROV

Urovant Sciences (UROV)

Urovant Sciences Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:UROV
DatumZeitQuelleÜberschriftSymbolFirma
13/04/202218h02Business WireUrovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 2022 American Urological Association Annual MeetingNASDAQ:UROVUrovant Sciences Ltd
07/03/202217h56Business WireUrovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902NASDAQ:UROVUrovant Sciences Ltd
20/12/202118h11Business WireUrovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® (vibegron) 75 mgNASDAQ:UROVUrovant Sciences Ltd
08/11/202114h00Business WireUrovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder PatientsNASDAQ:UROVUrovant Sciences Ltd
01/04/202112h14Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:UROVUrovant Sciences Ltd
31/03/202118h31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:UROVUrovant Sciences Ltd
31/03/202118h31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:UROVUrovant Sciences Ltd
31/03/202118h31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:UROVUrovant Sciences Ltd
31/03/202118h31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:UROVUrovant Sciences Ltd
31/03/202118h31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:UROVUrovant Sciences Ltd
31/03/202118h31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:UROVUrovant Sciences Ltd
31/03/202118h31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:UROVUrovant Sciences Ltd
31/03/202118h31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:UROVUrovant Sciences Ltd
31/03/202118h31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:UROVUrovant Sciences Ltd
31/03/202118h31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:UROVUrovant Sciences Ltd
30/03/202118h13Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:UROVUrovant Sciences Ltd
29/03/202121h13Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:UROVUrovant Sciences Ltd
29/03/202121h09Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:UROVUrovant Sciences Ltd
29/03/202121h06Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:UROVUrovant Sciences Ltd
29/03/202121h04Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:UROVUrovant Sciences Ltd
29/03/202114h44Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ...NASDAQ:UROVUrovant Sciences Ltd
29/03/202114h36Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:UROVUrovant Sciences Ltd
24/03/202121h30Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:UROVUrovant Sciences Ltd
19/02/202112h11Edgar (US Regulatory)Amended Statement of Ownership: Private Transaction (sc 13e3/a)NASDAQ:UROVUrovant Sciences Ltd
19/02/202112h05Edgar (US Regulatory)Proxy Statement - Merger or Acquistion (definitive) (defm14a)NASDAQ:UROVUrovant Sciences Ltd
16/02/202121h38Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:UROVUrovant Sciences Ltd
12/02/202123h43Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:UROVUrovant Sciences Ltd
12/02/202122h13Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:UROVUrovant Sciences Ltd
12/02/202122h05Business WireUrovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 ResultsNASDAQ:UROVUrovant Sciences Ltd
11/02/202114h00Business WireUrovant Sciences Announces Progression of URO-902 Phase 2a Trial Following Positive Recommendation from the Data & Safety Mon...NASDAQ:UROVUrovant Sciences Ltd
 Showing the most relevant articles for your search:NASDAQ:UROV

Kürzlich von Ihnen besucht

EU
SSSHD
Euronext S Shell 070322 ...
NYSE
MTL
Mechel PAO
BOV
PETRL31
PETRL31 Ex:21,13
NASDAQ
ACDCW
ProFrac
EU
SSBNG
Euronext S BNP 070322 GR...
TSXV
HELX
Helix Applications
BIT
P1VD44
NLBNPIT1VD44 20991231 28...
COIN
XFLOKIETH
XFLOKI
NASDAQ
AAWOYXX
Bank of Montreal Capped ...
BOV
Q1UE34
Quest Diagnostics
NASDAQ
ABABEXX
Bank of Montreal Atm Dig...
USOTC
WSSH
West Shore Bank (PK)
NASDAQ
AAYBAXX
Bank of Montreal Autocal...
USOTC
BPOSF
Bpost (PK)
MRTX
NDXETH
nDEX
USOTC
XNYIF
Xinyi Solar (PK)
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten